Ruxolitinib Phosphate

CAS 1092939-17-7 18 current recordsSmall Molecule

Who holds supplier records for Ruxolitinib Phosphate? 18 organisations hold a current record for Ruxolitinib Phosphate: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (11), China (4), United States (1) and Netherlands (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records

Cite as: PharmaTek, “Ruxolitinib Phosphate: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/ruxolitinib-phosphate

Reading the evidence

  • 18 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    11 of the 17 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 12 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (18)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Ruxolitinib Phosphate. Country is the organisation's recorded country, not necessarily the manufacturing site.

India11China4United States1Netherlands1Country not recorded for 1
Need Ruxolitinib Phosphate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Ruxolitinib Phosphate is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1795071).

Chemical identity

IUPAC name
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile;phosphoric acid
Canonical SMILES
C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
InChIKey
JFMWPOCYMYGEDM-XFULWGLBSA-N
Synonyms
INCB-018424 PHOSPHATE, INCB018424 PHOSPHATE, INCB-018424 SALT, INCB018424 SALT, INCB-18424 PHOSPHATE, Jakafi, Jakavi, Opzelura, Ruxolitinib (as phosphate), Ruxolitinib monophosphate, Ruxolitinib phosphate, CHEBI:66917

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Janus Kinase Inhibitor; Kinase Inhibitor
Mechanism of action
Janus Kinase Inhibitors

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Ruxolitinib Phosphate?

18 organisations hold an active US FDA Type II Drug Master File or a CEP for Ruxolitinib Phosphate: MSN Laboratories Private Limited (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), CHANGZHOU PHARMACEUTICAL FACTORY (China), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (China), CHONGQING HUAPONT PHARMACEUTICAL CO LTD and CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (China), and 10 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Ruxolitinib Phosphate Drug Master Files are active?

MSN Laboratories Private Limited (DMF 43832, 32221), Alembic Pharmaceuticals Limited (DMF 42347), ALIVUS LIFE SCIENCES LTD (DMF 41620), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 41012), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 39763), CHONGQING CARELIFE PHARMACEUTICAL CO LTD (DMF 44546), CHONGQING HUAPONT PHARMACEUTICAL CO LTD (DMF 29480) and CHONGQING HUAPONT SHENGCHEM PHARMACEUTICAL CO LTD (DMF 43550) and 10 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

How do I qualify a Ruxolitinib Phosphate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Ruxolitinib Phosphate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.